SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 and manifest infection outcomes ranging from severe disease to persistent infection. Weakened immune systems mean greater viral loads and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadevall, Arturo, Focosi, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014096/
https://www.ncbi.nlm.nih.gov/pubmed/36919696
http://dx.doi.org/10.1172/JCI168603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014096/
https://www.ncbi.nlm.nih.gov/pubmed/36919696
http://dx.doi.org/10.1172/JCI168603

Ejemplares similares